Cranberry-derived proanthocyanidins prevent formation of Candida albicans biofilms in artificial urine through biofilm- and adherence-specific mechanisms

Journal of Antimicrobial Chemotherapy

Volumn 69, Issue 2, 2014, Pages 428-436

  Rane, Hallie S ^a   Bernardo, Stella M ^a,b   Howell, Amy B ^c   Lee, Samuel A ^a,b  

^a NEW MEXICO VA HEALTH CARE SYSTEM   (United States)

^b UNIVERSITY OF NEW MEXICO HEALTH SCIENCES CENTER   (United States)

^c RUTGERS UNIVERSITY   (United States)

Author keywords

Cranberry PACs; Urinary catheters; Urinary tract infections; Vaccinium macrocarpon ait

Indexed keywords

AMPHOTERICIN B; ANTIFUNGAL AGENT; CASPOFUNGIN; FLUCONAZOLE; POLYSTYRENE; PROANTHOCYANIDIN DERIVATIVE; SILICONE;

ANTIFUNGAL ACTIVITY; ARTICLE; BACTERIAL METABOLISM; BACTERIAL STRAIN; BIOFILM; CANDIDA ALBICANS; CANDIDURIA; COMPARATIVE STUDY; CONTROLLED STUDY; CRANBERRY; CRANBERRY JUICE; FUNGUS HYPHAE; IN VITRO STUDY; INDWELLING URINARY CATHETER; IRON CHELATION; MINIMUM INHIBITORY CONCENTRATION; MUTANT; NONHUMAN; SPECIES; SUPPLEMENTATION; URINE; XTT ASSAY;

CRANBERRY PACS; URINARY CATHETERS; URINARY TRACT INFECTIONS; VACCINIUM MACROCARPON AIT.;

ANTIFUNGAL AGENTS; BIOFILMS; CANDIDA ALBICANS; HUMANS; PLANT EXTRACTS; PROANTHOCYANIDINS; URINE; VACCINIUM MACROCARPON;

EID: 84892459298     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkt398     Document Type: Article

References (59)

1. Achkar JM, Fries BC. Candida infections of the genitourinary tract. Clin Microbiol Rev 2010; 23: 253-73.
2. Kauffman CA. Candiduria. Clin Infect Dis 2005; 41 Suppl 6: S371-6.
3. Bougnoux M-E, Kac G, Aegerter P et al. Candidemia and candiduria in critically ill patients admitted to intensive care units in France: incidence, molecular diversity, management and outcome. Intensive Care Med 2008; 34: 292-9.
4. Morgan J, Meltzer MI, Plikaytis BD et al. Excess mortality, hospital stay, and cost due to candidemia: a case-control study using data from population-based candidemia surveillance. Infect Control Hosp Epidemiol 2005; 26: 540-7.
5. Cowen LE, Steinbach WJ. Stress, drugs, and evolution: the role of cellular signaling in fungal drug resistance. Eukaryotic Cell 2008; 7: 747-64.
6. Jain N, Kohli R, Cook E et al. Biofilm formation by and antifungal susceptibility of Candida isolates from urine. Appl Environ Microbiol 2007;73: 1697-703.
7. Lupetti A, Danesi R, Campa M et al. Molecular basis of resistance to azole antifungals. Trends Mol Med 2002; 8: 76-81.
8. Douglas LJ. Candida biofilms and their role in infection. Trends Microbiol 2003; 11: 30-6.
9. Malani AN, Kauffman CA. Candida urinary tract infections: treatment options. Expert Rev Anti Infect Ther 2007; 5: 277-84.
10. Klepser M. The value of amphotericin B in the treatment of invasive fungal infections. J Crit Care 2011; 26: 225.e1-10.
11. Butts A, Krysan DJ. Antifungal drug discovery: something old and something new. PLoS Pathog 2012; 8: e1002870.
12. Ramage G, Saville SP, Thomas DP et al. Candida biofilms: an update. Eukaryotic Cell 2005; 4: 633-8.
13. Wang X, Fries BC. A murine model for catheter-associated candiduria. J Med Microbiol 2011; 60: 1523-9.
14. Maki DG, Tambyah PA. Engineering out the risk for infection with urinary catheters. Emerg Infect Dis 2001; 7: 342-7.
15. Wang C-H, Fang C-C, Chen N-C et al. Cranberry-containing products for prevention of urinary tract infections in susceptible populations: a systematic review and meta-analysis of randomized controlled trials. Arch Intern Med 2012; 172: 988-96.
16. Tempesta M, Barrett M. Cranberry products prevent urinary tract infections in women: clinical evidence. In: Cooper R, Kronenberg F, eds. Botanical Medicine: From Bench to Beside. New Rochelle, NY: Mary Ann Liebert, 2009; 203-11.
17. Raz R, Chazan B, Dan M. Cranberry juice and urinary tract infection. Clin Infect Dis 2004; 38: 1413-9.
18. HowellAB, Reed JD, Krueger CGet al. A-type cranberry proanthocyanidins anduropathogenicbacterialanti-adhesionactivity. Phytochemistry2005;66:2281-91.
19. Gupta K, Chou MY, Howell AB et al. Cranberry products inhibit adherence of P-fimbriated Escherichia coli to primary cultured bladder and vaginal epithelial cells. J Urol 2007; 177: 2357-60.
20. Eydelnant IA, Tufenkji N. Cranberry derived proanthocyanidins reduce bacterial adhesion to selected biomaterials. Langmuir 2008;24: 10273-81.
21. Howell AB, Botto H, Combescure C et al. Dosage effect on uropathogenic Escherichia coli anti-adhesion activity in urine following consumption of cranberry powder standardized for proanthocyanidin content: a multicentric randomized double blind study. BMC Infect Dis 2010; 10: 94.
22. Hidalgo G, Chan M, Tufenkji N. Inhibition of Escherichia coli CFT073 fliC expression and motility by cranberry materials. Appl Environ Microbiol 2011; 77: 6852-7.
23. Feldman M, Tanabe S, Howell AB et al. Cranberry proanthocyanidins inhibit the adherence properties of Candida albicans and cytokine secretion by oral epithelial cells. BMC Complement Altern Med 2012; 12: 6.
24. Foo LY, Lu Y, Howell AB et al. A-type proanthocyanidin trimers from cranberry that inhibit adherence of uropathogenic P-fimbriated Escherichia coli. J Nat Prod 2000; 63: 1225-8.
25. Foo LY, Lu Y, Howell AB et al. The structure of cranberry proanthocyanidins which inhibit adherence of uropathogenic P-fimbriated Escherichia coli in vitro. Phytochemistry 2000; 54: 173-81.
26. Fonzi WA, Irwin MY. Isogenic strain construction and gene mapping in Candida albicans. Genetics 1993; 134: 717-28.
27. LaFleur MD, Kumamoto CA, Lewis K. Candida albicans biofilms produce antifungal-tolerant persister cells. Antimicrob Agents Chemother 2006; 50:3839-46.
28. Ramage G, Mowat E, Jones B et al. Our current understanding of fungal biofilms. Crit Rev Microbiol 2009; 35: 340-55.
29. Ramage G, López-Ribot JL. Techniques for antifungal susceptibility testing of Candida albicans biofilms. Methods Mol Med 2005; 118:71-9.
30. Pillai SK, Moellering RC, Eliopoulous GM. Antimicrobial combinations. In: Lorian V, ed. Antibiotics in Laboratory Medicine. 5th edn. Baltimore, MD: Williams & Wilkins, 2005; 365-440.
31. Clinical and Laboratory Standards Institute. Reference Method for Broth Dilution Antifungal Susceptibility Testing of Yeasts: Third Informational Supplement M27-S3. CLSI, Wayne, PA, USA, 2008.
32. Imbert C, Rodier MH, Daniault G et al. Influence of sub-inhibitory concentrations of conventional antifungals on metabolism of Candida albicans and on its adherence to polystyrene and extracellular matrix proteins. Med Mycol 2002; 40: 123-9.
33. Chamilos G, Lewis RE, Albert N et al. Paradoxical effect of echinocandins across Candida species in vitro: evidence for echinocandin-specific and Candida species-related differences. Antimicrob Agents Chemother 2007;51: 2257-9.
34. Melo AS, Colombo AL, Arthington-Skaggs BA. Paradoxical growth effect of caspofungin observed on biofilms and planktonic cells of five different Candida species. Antimicrob Agents Chemother 2007; 51: 3081-8.
35. Ku TSN, Bernardo SM, Lee SA. In vitro assessment of the antifungal and paradoxical activity of different echinocandins against Candida tropicalis biofilms. J Med Microbiol 2011; 60: 1708-10.
36. Lin B, Johnson BJ, Rubin R Aet al. Iron chelation bycranberry juice and its impact on Escherichia coli growth. Biofactors 2010; 37: 121-30.
37. Pérez-López FR, Haya J, Chedraui P. Vaccinium macrocarpon: an interesting option for women with recurrent urinary tract infections and other health benefits. J Obstet Gynaecol Res 2009; 35: 630-9.
38. Afshar K, Stothers L, Scott H et al. Cranberry juice for the prevention of pediatric urinary tract infection: a randomized controlled trial. J Urol 2012; 188: 1584-7.
39. Barbosa-Cesnik C, Brown MB, Buxton M et al. Cranberry juice fails to prevent recurrent urinary tract infection: results from a randomized placebo-controlled trial. Clin Infect Dis 2011; 52: 23-30.
40. Campbell G, Pickles T, D'yachkova Y. A randomised trial of cranberry versus apple juice in the management of urinary symptoms during external beam radiation therapy for prostate cancer. Clin Oncol (R Coll Radiol) 2003; 15: 322-8.
41. Cowan CC, Hutchison C, Cole T et al. A randomised double-blind placebo-controlled trial to determine the effect of cranberry juice on decreasing the incidence of urinary symptoms and urinary tract infections in patients undergoing radiotherapy for cancer of the bladder or cervix. Clin Oncol (R Coll Radiol) 2012; 24: e31-8.
42. Ferrara P, Romaniello L, Vitelli O et al. Cranberry juice for the prevention of recurrent urinary tract infections: a randomized controlled trial in children. Scand J Urol Nephrol 2009; 43: 369-72.
43. Kontiokari T, Sundqvist K, Nuutinen M et al. Randomised trial of cranberry-lingonberry juice and Lactobacillus GG drink for the prevention of urinary tract infections in women. BMJ 2001; 322: 1571.
44. Kontiokari T, Salo J, Eerola E et al. Cranberry juice and bacterial colonization in children-a placebo-controlled randomized trial. Clin Nutr 2005; 24: 1065-72.
45. McMurdo MET, Bissett LY, Price RJG et al. Does ingestion of cranberry juice reduce symptomatic urinary tract infections in older people in hospital? A double-blind, placebo-controlled trial. Age Ageing 2005; 34:256-61.
46. Stapleton AE, Dziura J, Hooton TM et al. Recurrent urinary tract infection and urinary Escherichia coli in women ingesting cranberry juice daily: a randomized controlled trial. Mayo Clin Proc 2012; 87: 143-50.
47. Takahashi S, Hamasuna R, Yasuda M et al. A randomized clinical trial to evaluate the preventive effect of cranberry juice (UR65) for patients with recurrent urinary tract infection. J Infect Chemother 2013; 19: 112-7.
48. Zhang L, Ma J, Pan K et al. Efficacy of cranberry juice on Helicobacter pylori infection: a double-blind, randomized placebo-controlled trial. Helicobacter 2005; 10: 139-45.
49. Patel KD, Scarano FJ, Kondo Met al. Proanthocyanidin-rich extracts from cranberry fruit (VacciniummacrocarponAit.) selectively inhibit the growth of human pathogenic fungi Candida spp. and Cryptococcus neoformans. J Agric Food Chem 2011; 59: 12864-73.
50. Lee YL, Najm WI, Owens J et al. Anti-microbial activity of urine after ingestion of cranberry: a pilot study. Evid Based Complement Alternat Med 2010; 7: 227-32.
51. Nohynek LJ, Alakomi H-L, Kähkönen MP et al. Berry phenolics: antimicrobial properties and mechanisms of action against severe human pathogens. Nutr Cancer 2006; 54: 18-32.
52. Cavanagh HMA, Hipwell M, Wilkinson JM. Antibacterial activity of berry fruits used for culinary purposes. J Med Food 2003; 6: 57-61.
53. Swartz JH, Medrek TF. Antifungal properties of cranberry juice. Appl Microbiol 1968; 16: 1524-7.
54. Lee YL, Owens J, Thrupp L et al. The antifungal activity of urine after ingestion of cranberry products. J Altern ComplementMed2009;15: 957-8.
55. Howell AB, Vorsa N, Der Marderosian A et al. Inhibition of the adherence of P-fimbriated Escherichia coli to uroepithelial-cell surfaces by proanthocyanidin extracts fromcranberries. N Engl JMed 1998; 339: 1085-6.
56. Huang Y, Nikolic D, Pendland S, Doyle BJ et al. Effects of cranberry extracts and ursolic acid derivatives on P-fimbriated Escherichia coli, COX-2 activity, pro-inflammatory cytokine release and the NF-κb transcriptional response in vitro. Pharm Biol 2009; 47: 18-25.
57. La VD, Howell AB, Grenier D. Cranberry proanthocyanidins inhibit MMP production and activity. J Dent Res 2009; 88: 627-32.
58. La VD, Howell AB, Grenier D. Anti-Porphyromonas gingivalis and anti-inflammatory activities of A-type cranberry proanthocyanidins. Antimicrob Agents Chemother 2010; 54: 1778-84.
59. Feldman M, Grenier D. Cranberry proanthocyanidins act in synergy with licochalcone A to reduce Porphyromonas gingivalis growth and virulence properties, and to suppress cytokine secretion by macrophages. J Appl Microbiol 2012; 113: 438-47.